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ABSTRACT: 
Although doxorubicin (DOX) has been widely investigated for treatment of different types of 
cancer, its poor cellular uptake and intracellular release still limit its further clinical 
applications (1). Due to their favourable characteristics, including the well-defined 
architecture, multivalency, and modifiable surface functionality, poly(amidoamine) 
(PAMAM) dendrimers have been extensively investigated for biomedical applications (2). 
However, most of the dendrimers are nondegradable, consequently resulting in high toxicity 
and uncontrollable drug release with limited release efficiency, which limits their further 
application in delivery of therapeutic agents (3). 
Low generation dendrimers are less expensive, possess a low number of defects and are more 
biocompatible than those of high generation. In this work degradable dendrimer nanoclusters 
were prepared by crosslinking of low generation PAMAM dendrimers (Generation 3, G3) 
using N, N’- cystamine-bis-acrylamide (CBA) as a disulphide containing cross linker. The 
synthesized G3-CBA was then PEGylated using methoxyl poly(ethylene glycol) carboxylic 
acid (m-PEG-COOH) (MW 2000 g/mol) for further improvement of the colloidal stability, 
which can be also helpful for prolonging the circulation period as well as reducing their 
toxicity, immunogenicity and antigenicity.  
The resulting G3-CBA-PEG dendrimers were characterised using Nuclear Magnetic 
Resonance (NMR), Fourier Transform Infra-Red Spectroscopy (FTIR), and Dynamic Light 
Scattering (DLS) to confirm the structure of G3-CBA and their PEGylated form (G3-CBA-
PEG). UV-Visible Spectroscopy technique was also performed to study the encapsulation of 
drug in the synthesized dendrimer nanoclusters. 
DOX, as a model drug was loaded into the resulting G3-CBA-PEG to obtain drug-loaded 
nanosystems (G3-CBA-PEG/DOX), which have been tested for anticancer drug delivery, 
concerning their drug release properties and anticancer cytotoxicity and cellular uptake 
through evaluation against CAL-72 cells (an osteosarcoma cell line). The results indicate that 
G3-CBA-PEG/DOX presented a pH and redox sensitive drug release in a sustainable way. 
The G3-CBA-PEG showed a reduced cytotoxicity than G3 dendrimers. G3-CBA-PEG/DOX 
presented a comparable anticancer cytotoxicity as compared with G3/DOX. The merits of the 
low generation PAMAM dendrimers, such as good cytocompatibility, sustained pH- and 
redox- dual cell responsive release properties, and improved anticancer activity, make them a 
promising platform for the delivery of other therapeutic agents beyond DOX. 
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RESUMO: 
A doxorrubicina (DOX) tem sido amplamente investigada para o tratamento de diferentes 
tipos de cancro. Contudo, a sua má internalização e libertação celular limitam ainda novas 
aplicações clínicas (1). Dadas as suas características favoráveis, onde se incluem  
a arquitectura bem definida, multivalência e possibilidade de modificação da superfície 
(funcionalização), os dendrímeros de poli(amidoamina) (PAMAM) têm sido amplamente 
investigados para aplicações biomédicas (2). No entanto, a maioria dos dendrímeros não são 
degradáveis, resultando numa alta toxicidade e libertação descontrolada do fármaco o que 
limita a sua eficiência de libertação e posterior aplicação na entrega de agentes terapêuticos 
(3). 
Neste trabalho prepararam-se dendrímeros PAMAM biodegradáveis por reticulação  
de dendrímeros PAMAM de baixa geração (Geração 3, G3) usando cistaminabisacrilamida 
(CBA) como um agente de reticulação contendo dissulfureto. Estes dendrímeros são mais 
baratos, apresentam um baixo índice de defeitos e são mais biocompatíveis que os de alta 
geração. 
O G3-CBA sintetizado foi posteriormente modificado com polietileno glicol (PEG) utilizando 
o m-PEG-COOH (MW 2000) para camuflá-lo do sistema imunitário do hospedeiro ou para 
uma imunogenicidade reduzida e antigenicidade. A modificação com o PEG também ajuda  
a aumentar o tamanho hidrodinâmico da droga o que proporciona um aumento do tempo  
de circulação, reduzindo a depuração renal. 
Os dendrímeros G3-CBA-PEG resultantes foram caracterizados por Ressonância Magnética 
Nuclear (RMN), Espectroscopia de Infra-vermelho com Transformada de Fourier (FTIR), 
Dispersão Dinâmica de Luz (DLS) e por espectroscopia de UV-Visível para confirmar  
a polimerização do G3-CBA, a modificação com o PEG do G3-CBA-PEG, para medir  
o tamanho hidrodinâmico do nano-cluster e para caracterizar e medir o encapsulamento  
de doxorrubicina em G3-CBA-PEG. 
A DOX, como um fármaco modelo, foi encapsulada no G3-CBA-PEG para obter 
nanosistemas (G3-CBA-PEG/DOX). Estes foram posteriormente testados em células CAL-72 
(linha celular de osteosarcoma) para entrega deste fármaco anticancerígeno, considerando  
as suas propriedades de libertação, citotoxicidade e internalização celular. O sistema  
G3-CBA-PEG/DOX revelou uma libertação controlada do fármaco que era dependente do pH 
e das condições de oxidação-redução. O G3-CBA-PEG exibiu uma citotoxicidade inferior  
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à dos dendrímeros G3 e o sistema G3-CBA-PEG/DOX apresentou uma citotoxicidade 
anticancerígena comparável à do G3/DOX. Os atributos dos dendrímeros PAMAM de baixa 
geração, a boa citocompatibilidade, a capacidade de reposta celular e a libertação do fármaco 
controlada e dependente do pH e das condições de oxidação-redução, e atividade 
anticancerígena melhorada, fazem deles uma promissora plataforma para entrega de outros 
agentes terapeuticos além da DOX. 
Palavras-chave: Dendrímeros; nanoagregados; doxorrubicina; entrega de fármacos. 
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CHAPTER 1 – INTRODUCTION  
 
1.1 Introduction to dendrimers 
 
Dendrimers are branched three-dimensional molecules which possess uncustomary molecular 
architectures and unique properties that make these alluring materials for the advancement of 
nanomedicines (4). 
Dendrimers are mainly composed of three distinguishable domains (Figure 1): 
(i) A single atom or an atomic group having at least two similar chemical functions as 
a central core  
(ii) Branches evolving  from the core, integrated of repeat units with at least one 
branch junction, whose iteration is organized in a geometrical progression which 
finally results in a series of deviated concentric layers called generations, and  
(iii) Many terminal functional groups, which are usually positioned on the periphery of 
the macromolecule, which play an important role in the physico-chemical 
properties. 
 
 
Figure 1 – Structure of dendrimer (5). 
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1.2 Approaches to synthesize dendrimers 
 
Dendrimers are generally large molecules with high molecular weight, regular and massively 
branched structures; these macromolecules are multivalent and their dimensions resembles to 
those of small proteins. Synthetically these high molecular weight and well organised 
structures are generally synthesized via a cascade synthesis using an iterative sequence of 
reaction steps. 
Dendrimers can be synthesized in each of these portions to have different functionality to 
control properties such as thermal stability, solubility, and for attachment of molecules for 
desired applications. Typical properties, such as the size and shape of the dendrimers as a 
function of generation, monomer distribution, solvent accessible surface area, and distribution 
of terminal groups are some of the critical aspects needed to be considered for some 
applications of dendrimers (6). 
Generally, there are two synthetic strategies commonly used for development of dendrimers 
with different compositions and/or surface termini (7-14). 
I. Divergent manner 
II. Convergent manner 
 
1.2.1 Divergent dendrimer synthesis  
 
The divergent method was pioneered by Tomalia et al. (15). The synthesis of dendrimers is 
assembled from a multifunctional core building block, which is further extended outward 
radially by a series of reactions (Activation and Coupling), commonly by Michael reactions. 
Each reaction step must be handled very carefully and must be driven to full completion in 
order to avoid imperfections in the dendrimer structure. These imperfections can cause 
trailing generations (the phenomenon of having branches at different lengths and sizes) (16). 
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The synthesis of dendrimers takes by a stepwise layer-by-layer modification (Activation and 
Coupling) which starts from the core and eventually builds the molecule towards the 
periphery using two basic chemical manoeuvrings (17). 
Firstly, the building blocks (branches) are coupled to the central core of the dendrimer which 
is the initiative of building the dendrimer structure. After that, the surface-group 
functionalities of the attached building blocks are modified (activated) for further growth. 
Higher generations of dendrimers can be prepared by repeating the reaction steps (18). The 
step by step reaction of the divergent synthesis of dendrimers is shown in Figure 2. 
 
Figure 2 – Divergent synthesis of dendrimers. A= active unprotected functional group, P= 
protected, inactive (protective group) functionality,     = core of the dendrimer, C= coupling 
group. Activation and Coupling are two repetitive steps contributing to the generation of 
Dendrimers (21). 
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1.2.1.1 Advantages of divergent synthesis 
 Divergent synthesis is generally simple and controllable. 
 Dendrimers with high molecular weight can be attained with a possibility of 
automation of the repetitive reaction steps. 
 This method is highly recommended and normally used in the commercial production 
of Poly(amidoamine) PAMAM dendrimers (19). 
1.2.1.2 Disadvantages of divergent synthesis 
 Steric effects play an important role in the synthesis of high generation dendrimers as 
they can cause trailing generations. 
 Impurities can have a greater impact on the functionality and symmetry of the 
dendrimer. 
 The relative size difference between imperfect and perfect dendrimers is very small; 
hence purification and separation of dendrimers are very difficult (20). 
 
1.2.2 Convergent dendrimer synthesis  
 
The convergent strategy was first developed by Fréchet and Hawker in their synthesis of 
polybenzylether containing dendrimers with highly monodispersed dendrimer structures (21).  
To circumvent the increasingly low reactivity accomplished during stepwise divergent 
synthesis, segment coupling strategies were applied to synthesise large oligopeptides of solid-
phase. With the advancement of this new approach in peptide synthesis, one more step further 
was taken towards pure chemical synthesis of high molecular weights. This strategy of 
segmental coupling or convergent strategy was handy for the creation of dendritic 
macromolecular structures (22).  
In contrast to the divergent method, the convergent method assembles a dendrimer from the 
periphery and inwards towards the core (outside inwards), by mostly “one to one” coupling of 
monomers therefore fabricating dendritic branches, dendrons, of increasing size as the 
synthesis process advances. 
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The final part of the convergent synthesis finishes up at the central core, where two or more 
dendritic segments (dendrons) will be joined together to form the dendrimer; the convergent 
strategy thus commonly has an inverse propagation correlated to the divergent strategy. The 
reaction steps involved in the convergent synthesis is shown below (Figure 3). 
 
 
 
Figure 3 – Convergent synthesis of dendrimers. F= functional group, P= protective group, C= 
coupling group    = core of the dendrimer. Reaction steps a) coupling and b) selective 
activation can be repeated until all segment-shaped dendrons of desired generation reacts with 
an oligo functional core module (C3) to form the higher generation (21). 
 
1.2.2.1 Advantages of convergent synthesis 
 The number of reactive sites during the propagation process remains minimal leading 
to faster reaction rates and maximum yields. 
 The most important advantage of this method is the large “molecular difference” 
between the reactant molecule and the product, which can facilitate the purification of 
the reactants from the product. 
 Asymmetric dendrimers can be synthesised by coupling different segments together to 
obtain dendrimers with heterogeneous morphologies using convergent synthesis. 
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 Several “active sites” can be incorporated in one dendrimer to synthesize 
heterogeneous dendrimers with multifunctional molecular structures (23). 
 
1.2.2.2 Disadvantages of convergent synthesis 
 Only low generation dendrimers can be produced generally by this method due to the 
steric hindrance which limits the dimensions of the dendrimer growth during the 
reaction of dendrons at the periphery. 
 As the generation of dendrimer increases, the reactive groups are densely covered at 
the focal point of the dendrons, and the attachment of the segmented units to the core-
fragment becomes difficult (24). 
 
1.2.3 Other synthetic methods for the synthesis of dendrimers 
 
There are several other methods which are commonly used in the synthesis of dendrimers, 
they are (10-14, 25-26): 
1) Click chemistry  
2) Orthogonal synthesis 
3) Double stage convergent method 
4) Double exponential method 
5) Hyper-monomer method 
6) Solid phase synthesis 
7) Co-ordination chemical synthesis 
8) Supramolecular assembly. 
These methods are not recommended for the production of dendrimers on a commercial scale 
but can be practised in laboratories and research institutions.  
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1.3 Physico-chemical properties of dendrimers 
 
Dendrimers are monodispersed macromolecules. The key properties of dendrimers include 
circumscribed architecture, globular shape, low polydispersity index, and a high ratio of 
multivalent surface moieties to molecular volume which determines these nanoscaled 
materials highly fascinating for the evolution of synthetic (non-viral) vectors for therapeutic 
nucleic acids (27-29).  
Unlike linear polymers, dendrimers show some significant improved physical and chemical 
properties because of their unique molecular structure. The presence of a large number of 
terminal groups is responsible for high reactivity, miscibility and for higher solubility.  The 
solubility of the dendrimers is strongly influenced by the nature of terminal groups. 
Dendrimers which have hydrophilic terminal groups are soluble in polar solvents, while 
dendrimers terminated in hydrophobic groups are soluble in non-polar solvents (30). 
Because of their unique globular shape and presence of internal cavities, dendrimers possess 
unique properties such as encapsulation of the guest molecules in their macromolecule 
interior (31-33). This unique property has opened a new way to encapsulate drugs, genes, 
proteins and other chemotherapeutics which are recently being used in numerous clinical 
applications. 
“Cationic” dendrimers (e.g., amine terminated PAMAM and poly(propyleneimine) (PPI) 
dendrimers that form cationic groups at low pH) are generally haemolytic and cytotoxic. 
Their toxicity is generation-dependent and increases with the number of surface groups (34). 
While “Anionic” dendrimers, bearing a carboxylate surface group, are not cytotoxic over a 
broad concentration range (35). These biological properties play a crucial role in using 
dendrimers in biomedical applications.  
In solution, linear polymer chains forms flexible coils; in contrary, dendrimers exist as a 
tightly packed ball (30). The viscosity of the dendrimer solutions is significantly lower than 
linear polymers (31). The intrinsic viscosity reaches maximum at generation 4 and then it 
begins to decrease when the molecular mass of dendrimers increases (28). Such behaviour is 
in contrast with linear polymers. For classical polymers when the molecular mass is increased 
the intrinsic viscosity increases continuously.  
The properties of the dendrimers are also influenced by the functional groups present on the 
periphery. However, dendrimers with internal functionality were also reported (37-39). 
 8 
 
Moreover, it is easier to make dendrimers water soluble, by functionalizing their terminal 
groups with hydrophilic groups or charged species. Other desirable and controllable 
properties of dendrimers include crystallinity, and chirality (40). 
Numerous researches are being carried out to investigate the physico-chemical properties of 
dendrimers applying chemical analytical techniques and computer simulations. In order to 
optimise the computer models to deliver a prudent picture, comparative studies are being 
carried out between predictions based theoretical calculations and experimental results by 
chemical analysis (41-42). 
Additionally, dendrimer chemistry is very alterable thus promoting broad range synthesis of 
various molecules with different functionality.  
The two most important dendrimers which are used commonly are (7, 43- 44) 
1)  PAMAM 
2) PPI. 
These dendrimers have been produced industrially and are commercially available up to 10 
generations.  
 
1.4 PAMAM dendrimers 
 
PAMAM dendrimers consist of polyamide branches with tertiary amines as focal points. 
After the initial report by Tomalia and co-workers (45-46) in the mid-1980s, PAMAM 
dendrimers have found numerous applications, ranging from gene therapy to molecular 
encapsulation and drug delivery, from micelle mimics as decontaminating agents to building 
blocks for nanostructures (8) and also provide many pharmaceutical, medicinal and clinical 
applications. 
PAMAM dendrimers (Figure 4) are commercially available from Dendritech Inc. laboratories, 
usually as methanol solutions up to 10 generations, having terminal or surface amino groups 
(NH3) (full generations) or carboxylic acid groups (COOH) (half-generations). Starburst 
dendrimers are applied as a trademark name for a sub-class of PAMAM dendrimers based on 
a tris-aminoethylene-imine core. This class of dendrimers are generally known with the 
abbreviation PAMAM. Fréchet-type dendrimers are a more recent type of dendrimer.  
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Figure 4 – Chemical structure of amino-terminated G3-PAMAM dendrimer (47) 
  
PAMAM dendrimers are the most extensively studied macromolecules with spheroidal or an 
ellipsoidal shape. Due to the distinct synthesis process, PAMAM dendrimers have many 
interesting properties, which differentiate these macromolecules from classical linear 
polymers. Moreover, PAMAM dendrimers possess many functional peripheral groups and 
empty internal cavities, which play a most important role in increasing the solubility and 
attaining a high reactivity. The special structure and the more number of surface amino 
groups (NH2) in PAMAM dendrimers may be expected to have numerous potential 
applications in increasing the solubility of the low aqueous solubility drugs or as delivery 
systems for bioactive reagents. 
The unique synthesis of these dendrimers in a stepwise manner from monomer units allows 
the refined control over the dimensions, polarity, flexibility, size, solubility, shape, density 
and placement of different functional groups by choosing these building units and functional 
group chemistry. As a result, they have the combination of typical characteristics of small 
organic molecules and polymers that result in special physico-chemical properties. 
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Accordingly, PAMAM dendrimers have captivated increasing attention for their applications 
in many fields including drug delivery, gene delivery, etc (46, 48). 
 
1.4.1 pH effect on PAMAM dendrimers 
 
Amino-terminated PAMAM dendrimers have basic surface groups as well as a basic interior. 
At pH 7.4, most of the primary amines are protonated, and by pH 4.0 all of the tertiary amines 
are also protonated (49). Low pH commonly leads to extended conformations due to 
electrostatic repulsions between ammonium groups. At pH≤ 4 the interior is hollow as a result 
of repulsion between the tertiary amine groups in the interior and the positively charged 
amine groups on the surface. At pH≥ 10 the charge of the molecule becomes neutral, as the 
repulsive forces between the surface groups and the interior groups are very low and hence it 
contracts forming a spherical structure. Under physiological conditions (pH 7.4), the 
formation of strong hydrogen bonds between the surface amine groups (positively charged) 
and neutral or uncharged tertiary amines on the branches back-folding of the dendrimers 
occurs. Therefore, the PAMAM dendrimers indicate different properties under different pH 
values, which can be used for fabrication of pH sensitive platforms for therapeutic delivery 
systems (50-51). 
 
1.5 Biomedical applications of dendrimers 
 
Dendrimers are the most promising macromolecular structures which are being extensively 
studied in the recent years. Their globular structure and the desirable properties of the 
dendrimers made extensive progress in the field of life science. Dendrimers are considered 
promising structures in many clinical applications (52-53).  The merits of dendrimers endow 
them with a variety of biomedical applications, such as drug delivery (54-56), gene 
transfection (57-59), magnetic resonance imaging (MRI) (60-66), bio-sensors (67-68), nano-
scaffolds (69-72), therapeutics (drug and gene delivery) (73-75), nano drugs (76-78), 
diagnostics, etc..  
Dendrimers as drug delivery systems are now creating opportunities for the studies in 
formulating efficient systems with drug stability and effective drug delivery to the targeted 
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sites.  Some of the advantages of using dendrimers as drug delivery systems include a 
controlled release of the drug in the circulatory system (79), the accumulation of nanoparticles 
(NPs) at the target sites, protecting the drug form the external environment, reducing the 
unwanted side effects of the therapeutic agents (80). Recent research also shows that 
modifying the surface groups of the dendrimers can also affect the cytotoxicity and 
degradability of the dendrimers.  
 
1.6 Dendrimers as drug delivery systems 
 
Dendrimers often have been used as vehicles for drug delivery. Encapsulation of anti-cancer 
drugs (cisplatin and doxorubicin (DOX)) within PAMAM dendrimers showed sustainable 
drug release, reduced toxicity and improved drug accumulation in tumour cells/tissues when 
compared with the free drugs (81).  
The three important reasons that justify the use of dendrimers for drug delivery are (82- 84): 
i. Dendrimers are large structures with many terminal groups which can be modified 
with different substances that are capable of targeting receptor sites on cells. 
ii. Formulation of many insoluble free drugs with dendrimers could enhance the 
solubility and thus increase the bioavailability.  
iii. Dendrimers have large structures that exceed renal clearance and are not filtered out 
by the kidneys. Furthermore, the nanometric size may induce the Enhanced 
Permeability and Retention (EPR) effect.  
Considering the above mentioned reasons which make the dendrimers more suitable for drug 
delivery, five different types of interactions are generally practiced for the encapsulation of 
drugs in dendrimers, which are shown in the Figure 5. 
i. Synthesis of dendrimer prodrugs by covalently attaching the drug to the periphery of 
the dendrimer or by cleavable bond (case A and B). 
ii. The drug is interacted non-covalently with the internal structure or to the outer 
functional groups (case C and D). 
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iii. Encapsulating the drug through the formation of a dendrimer-drug supramolecular 
assembly in which the dendrimer acts as a kind of macromolecular micelle (case E 
and F) (85-86). 
 
 
Figure 5 – Schematic representation of types of formulations for encapsulation of drug in 
dendrimers. Covalent attachment of the drug (case A and B); Non-covalent attachment of the 
drug (case C and D); Dendrimer drug-based supramolecular assembly (case E and F) (87). 
 
Dendrimers are being widely studied for the controlled drug release, increased encapsulation 
of drugs, cellular uptake and for the increased retention time in the circulatory system. The 
encapsulation of the drug normally increases with the increase in the generation of the 
dendrimers, but due to cytotoxic effects of the higher generation dendrimers, generation 3-5 
are considered as effective drug release systems (88). 
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1.6.1 Targeted drug delivery 
 
Many anticancer drugs are available in the markets which are effective in killing the tumour 
cells, but due to their cytotoxic properties most of them are not being used in clinical 
applications. Numerous targeted drug delivery systems have been introduced and are being 
developed to optimize regenerative techniques. This targeted drug delivery system is based on 
an approach that is capable of delivering a certain amount of a therapeutic agent/drug for an 
extended period of time to a targeted tumour within the body. This method helps in 
maintaining the tissue drug levels and required plasma in the body, hence reducing 
cytotoxicity to the normal tissues (89). 
 
 
Figure 6 – Approach to design targeted drug delivery systems (90). 
 
To design a system for targeted drug delivery requires plenty of effort and an excellent 
knowledge about the physiochemical activities occurring in the body. Ideal targeting drug 
delivery systems should present the following ideal characteristics (91-92): 
a) They should be non-toxic and non-immunogenic,  
b) They must present sufficient stable circulation period,  
c) Drug release from the system into the target should not affect the drug action or its 
properties,  
d) The systems must be degradable after the drug is released and should be eliminated 
from the body without causing any long term side effects to the normal cells,  
e) Drug release should be controllable. 
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Targeted drug delivery systems are more effective than the classical drug delivery methods as 
they specifically target the tumour cells without interacting with the normal cells in the body. 
There are several kinds of strategies to direct the system to the tumour cells/tissues. In general 
two types of strategies can be followed 
1) Active drug delivery system can be described as the system carrying the drug binds with 
the targeting molecules (proteins/folic acid) which have receptors for the targeted cells, which 
induce direct cellular uptake. This type of approach is also called as receptor mediated cellular 
uptake (93). 
2) Passive drug delivery is based on the EPR effect. In order to grow rapidly the tumour cells 
must stimulate the production of blood vessels and other growth factors. To accumulate in the 
tumour, cells tend to take advantage of the increased permeability of the cancer blood vessels 
to take up the particles during circulation in the blood. As a result of this reaction the drug 
entrapped in the system can be released into the cells (94).  
 
1.7 Degradable dendrimers using cross link molecules for drug and gene delivery 
 
Degradable or cleavable dendritic structures (including dendrimers and hyper-branched 
polymers) have been unveiled for various applications, such as drug and gene delivery (95), 
molecular imprinting (96),  generation of materials with microcavities (97) and release of 
fragrances and flavors (98) in which these structures function as a “covalent reservoir” (99). 
Crosslinking is the most important concept in polymer chemistry and is extensively used in 
the fabrication of different materials for many applications. Due to the advancement in 
technology and research by the researchers, the crosslinking methodology has been 
developing rapidly. Cross linkages are not only used to link one polymer chain to another, but 
are also used to link other various chemical moieties together. A variety of crosslinking 
agents have been introduced in the recent years, such as acrylates (100-101), esters (102-103), 
olefins, organosilicons (104-106) to dendrimers, which have broad applications in the field of 
science. Cross linkage helps in easy dissolution in water and provides degradation of chemical 
species linked to them. Cross link chemistry is very reliable and hasfound many applications 
in drug and/or gene delivery.  
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Recent studies have shown that the degradability of dendrimers is enhanced when a 
disulphide cross link is used. The rapid cleavage of the disulphide linkages in the intracellular 
reductive environment (containing 0.1–10 mM glutathione) is biologically relevant to induce 
fast dissociation and efficient release of drugs and DNA. These studies also show that the 
degradability and release rates were lower at 20-40% of disulphide content, but were higher 
when more than 60% of the disulphide cross linked molecules were used. The disulphide 
content in these cross linked molecules also influence the transfection efficiency and cell 
viability. When more increments of disulphide content are added (more than 85 %), the 
formed materials have only marginal effects on the transfection efficiency and degradability 
(107).   
 
1.8 PEGylation 
 
In order to increase the possibility of nanomedicines to be accumulated around the tumour 
tissues, circulation time needs to be prolonged. Poly(ethylene-glycol) (PEG) is nontoxic, non-
immunogenic, non-antigenic, and highly soluble in water and has been approved by the Food 
and Drug Administration (FDA) for human oral, intravenous and dermal pharmaceutical 
applications (108). Therefore, PEG has a crucial role in drug delivery and in designing the 
drug delivery systems. PEGylation through which PEG polymer chains are attached to 
another molecule by means of covalent bond is one of the most popular methods to achieve 
this purpose.  
 PEG is able to act as a protective coating constituent for drug delivery nanosystems (109-
110), and has also contributed to the similar protection as a covalently bond conjugate to other 
drug molecules (111) and proteins (112). PEG is thus soluble in a wide variety of solvents 
(both non-polar and polar solvents) (113). Due to its important characteristics as a protective 
layer, PEG is often used to enhance the aqueous solubility or dissolution characteristics of 
hydrophobic drug molecules (114-116). 
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1.8.1 PEGylation strategies 
 
PEGylation is typically an additional step, implemented at the end of an already existing 
process for the production of a given dendrimer. Several strategies have been proposed by 
many authors. There are different PEGylation strategies: site specific mono PEGylation is a 
generally practised technique in which highly reproducible products with maximum activity 
are produced.  PEG also has an advantage of delivering the systems invisible to the liver, 
blood and splenic macrophages promoting retention in the diseased organ or blood. These 
types of carriers can act as a suitable platform in treating cancer by long circulatory lifetime 
of particles and by entrapment in the leaky vasculature of tumour (117). Alkylation is a 
technique which maintains the positive charge of the former amino group because of the 
formation of the secondary amine, or acylation, followed by loss of charge (118,119). The 
other PEGylation techniques include non-specific PEGylation, non-covalent PEGylation etc. 
PEGylated dendrimers are generally biocompatible and show increased solubility when 
compared with the free molecules. These molecules provide complete packing for the drug 
and protect from different environments (pH conditions) and show a sustainable release (120). 
Various materials like multiple drugs, imaging agents, and DNA can be introduced as the 
PEGylated dendrimers provides more space (Figure 7).  
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Figure 7 – Multiple materials introduced into PEGylated Dendrimer (121). 
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1.8.2 Advantages of PEGylation 
 
PEGylation has many significant pharmacological advantages over the unmodified form by 
increasing the molecular weight of a molecule such as (122): 
 Improved drug solubility 
 Reduced dosage frequency, without diminished efficacy with potentially reduced 
toxicity 
 Extended circulation lifetime 
 Increased drug stability 
 Enhanced protection from proteolytic degradation 
 Water solubility 
 High mobility in solution 
 Lack of toxicity and low immunogenicity 
 Altered distribution in the body 
 
 1.8.3 Limitations of PEGylation  
 
PEG is attained by chemical synthesis and, like all synthetic polymers, it is polydispersed, 
with different number of monomers resulting in a Gaussian distribution of the molecular 
weights. This leads to a population of drug conjugates, with different biological properties, 
mainly in circulation time inside the body and immunogenicity. 
A second problem reported with the use of this polymer is related with the renal clearance 
from the body. PEGs are usually excreted in urine or faeces but PEG with high molecular 
weights (>10000 k.Da) can long-term accumulate in the liver, leading to macromolecular 
syndrome (110). 
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1.9 Objectives and general strategies of the thesis 
 
The main objective of the present project work was to synthesize degradable PEGylated 
dendrimer nanoclusters and investigate these nanosystems for delivery of an anticancer drug 
model, DOX. The nanoclusters were prepared via in situ crosslinking of low generation 
PAMAM dendrimers by N,N’-cystamine-bis-acrylamide (CBA) followed  by PEGylation 
using carboxylated mPEG (molecular weight: 2000 g/mol). The synthesized compounds were 
characterized by using 
1
H NMR and FTIR to confirm the polymerisation and PEGylation 
reaction (Figure 8). Size analysis and stability tests were performed for the synthesised 
particles for their effective use as drug delivery systems. Then, the drug release kinetics was 
studied in vitro using different pH conditions and reducible cell mimic conditions. Later, 
biological evaluation was performed by treating CAL-72 (osteosarcomal) cells with the drug-
loaded nanosystems concerning their anticancer cytotoxicity and therapeutic efficacy. Cellular 
uptake tests were performed to check the internalization process of nanoclusters inside the 
cells and therapeutic accumulation intracellularly. 
 
 
Figure – 8 Synthesis procedure of G3-CBA-PEG/DOX 
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CHAPTER 2 – MATERIALS AND METHODS 
 
2.1 Materials and Reagents 
 
Generation 3 PAMAM dendrimers possessing ethylenediamine cores and amine termini 
(PAMAM G3 M.W. = 6909 g/mol with 32 NH3 surface groups) in methanol solution, were 
purchased from Dendritech Inc. N, N’- Cystamine-bis-acrylamide (CBA, 98% purity) was 
purchased from SIGMA-ALDRICH.  Triethylamine (TEA, purity > 99%) was purchased 
from MERCK. m-PEG-COOH was purchased from Yare Bio (China). Thioglycolic acid 
(TGA, purity 99%) was purchased from SIGMA-ALDRICH.  Unless otherwise stated, all 
other chemicals were obtained from SIGMA-ALDRICH and used as received. Cell culture 
dishes were purchased from Nunc. The dialysis membranes were bought from Spectrum
®
 labs 
and the filters used for solution sterilization were obtained from VWR
™
 with a pore size of 
0.22 μm. 
 
2.2 Synthesis of G3-CBA-PEG dendrimer nanoclusters 
 
Crosslinking of PAMAM G3 dendrimer with N,N’-cystamine-bis-acrylamide (CBA) was 
carried out at 37
 o
C for 3 days. 
The synthesis involves the following steps:  PAMAM G3 (20 mg, 0.002894 mmol) was 
dissolved using 1 mL of methanol in an eppendorf. In another eppendorf CBA (0.75 mg, 
0.002894 mmol) (1:1 mmol ratio) was dissolved in 1 mL of methanol. Then the dissolved 
CBA solution was dropwisely added to PAMAM G3 dendrimer solution at room temperature 
carefully using a micropipette. The reaction mixture was kept at 37
0
 C for three days for the 
reaction completion. The finally formed reaction mixture was dialysed against Phosphate 
Buffered Saline (PBS) (pH 7.4, 3 times 3 L) through a dialysis membrane (Molecular Weight 
Cut Off (MWCO) of 2000 Da) for 24 hours, and against distilled water (3L 3 times a day) for 
two days to remove methanol and free CBA molecules. This was followed by lyophilization 
for 3 days to get G3-CBA dendrimer nanoclusters.  
 The final product (G3-CBA dendrimer nanoclusters) was analysed with 
1
H NMR to confirm 
the successful reaction of CBA with G3 PAMAM. 
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2.3 The effect of CBA/G3 ratio on the formation of the dendrimer nanoclusters 
 
Different ratios of CBA to PAMAM G3 were used (1:1, 1:2, 1:3 and 1:4) to study the effect 
of CBA and the content of disulphide linkage on the drug release properties, 
cytobiocompatibilty and the cytotoxicity. The synthesis was performed using the process 
mentioned above in Section 2.2. The materials required for the synthesis are shown in Table 
1.  
Table 1 – Materials required for the synthesis of G3-CBA dendrimer nanoclusters with 
different ratios of CBA (amount of methanol used in all assays: 2 mL). 
 
Ratio 
(G3:CBA) 
 
Amount of G3-PAMAM 
mmol 
 
Amount of CBA 
mmol 
 
1:1 
 
0.002894  
 
0.002894 
 
1:2 
 
0.002894 
 
0.005788 
 
1:3 
 
0.002894 
 
0.008682 
 
1:4 
 
0.002894 
 
0.01157 
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2.4 PEGylation of G3-CBA 
 
mPEG-COOH (molecular weight 2000 g/mol) was used to PEGylate the synthesised G3-CBA 
dendrimer nanoclusters. mPEG-COOH (0.036185 mmol) in the 1:5 molar ratio of  G3:mPEG 
was dissolved in 1.5 mL of water. The terminal OH groups of the mPEG-COOH were 
activated using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (0.108554 mmol) 
dissolved in 1.5 mL of water.  The EDC solution was then added in a dropwise manner using 
a micropipette. Then the reaction mixture was kept at room temperature for 3 h with 
continuous moderate stirring to activate the –COOH group of the mPEG-COOH. Then, the 
addition of G3-CBA (50 mg) in 1 mL of water was dropwisely added to the activated mPEG-
COOH solution mixture. The reaction was carried out for 3 days at room temperature with 
continuous moderate stirring. The final compound obtained was then dialysed using a dialysis 
membrane (MWCO of 2000 Da) against distilled water (3 times 3L) for 3 days to remove the 
excessive by-products, followed by lyophilization for 3 days to obtain the G3-CBA-PEG 
dendrimer samples in a white solid state. The chemicals used for the PEGylation reaction are 
mentioned in Table 2. 
 
Table 2 – Feed ratio for the PEGylation of G3-CBA dendrimer nanoclusters. 
Chemicals 
 
Mw, g/mol 
Weight 
mg mmol Mol ratio UP water, ml 
G3
*
 
 
6909 50.000 0.007237 1 1 
mPEG-COOH 
(2000) 
 
2000 72.369 0.036185 
 
1:5 1.5 
EDC 
 
155.24 16.852 0.108554 1:15  1.5 
G3
* 
is the base quantity of the chemical used, the ratios of mPEG and EDC were taken as 
mentioned above in mmol ratio to G3 ratio. 
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2.5 Characterization of G3-CBA-PEG dendrimer nanoclusters  
 
1
H NMR spectra of the final product G3-CBA-PEG and the intermediate product (G3-CBA) 
were recorded using a Bruker Advance II+ 400MHz NMR spectrometer. 0.4-0.5 mg of the 
samples was dissolved in 500-600 μL D2O before measurements. FTIR analysis (Perkin 
Elmer Spectrum II) was performed for all the starting materials (G3-PAMAM, CBA and 
mPEG-COOH), the intermediate products (G3-CBA) and the final product G3-CBA-PEG. 
Samples were vigorously mixed by grinding the samples (G3-PAMAM, CBA, and G3-CBA-
PEG) with KBr using ratio of 1:5 and were then subjected under hydraulic pressure of 10 tons 
to prepare pellets or disks for analysis using FTIR.  
Analysis of encapsulation of DOX into the dendrimer nanoclusters was performed by UV-Vis 
spectra using a Lambda 2 UV-Vis spectrometer (Perkin-Elmer). Before measurement, 
samples containing DOX were dissolved in methanol.  
 
2.6 Study of size and stability of synthesized compounds 
 
Size measurements were performed for the samples (G3-CBA-PEG 1:1, 1:2, 1:3, 1:4 and G3-
CBA-PEG/DOX 1:1, 1:2, 1:3, 1:4) to measure the hydrodynamic size of the modified 
dendrimers at pH 7.0, using a Zetasizer (Malvern). Samples were dissolved in 1 mL of PBS 
(pH 7.4) before the measurements. 
100 µg of the samples were dissolved in 1 mL of water and were well-sealed with parafilm 
and were kept at room temperature. Hydrodynamic sizes of the particles (drug loaded and 
non-loaded) were measured after every 24 h for 10 days using the Zetasizer Nano ZS system.  
 
2.7 Encapsulation of DOX within G3-CBA-PEG dendrimer nanoclusters 
 
G3-CBA-PEG dendrimer nanoclusters (3 mg) were dissolved in 1 mL water. Doxorubicin 
hydrochloride (DOX・HCl) with 10 molar equivalents of dendrimers was dissolved in 150 
μL methanol followed by adding 5 μL TEA to generate non-protonated DOX (130). Then the 
dendrimer aqueous solution was added carefully in a dropwise manner to the non-protonated 
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DOX solution and was stirred vigorously for 12 h, allowing the evaporation of the methanol 
solvent. After that, the solution mixture was centrifuged at 23
 o
C (10000 rpm for 10 min) in 
order to remove the precipitates, which were due to non-complexed free DOX. The 
supernatant was removed carefully and was lyophilized for 3 days to obtain the G3-CBA-
PEG/DOX complex. The precipitate obtained was preserved and re-dissolved into 8 mL 
methanol for indirect determination of the encapsulated amount of DOX by UV-Vis analysis. 
The DOX loading process of G3 was similar except replacing G3-CBA-PEG with G3, and the 
obtained G3/DOX was used as control sample for further study. 
The encapsulation efficiency of the dendrimer nanoclusters were calculated using the formula 
 
2) Encapsulation = Amount of the DOX used        Unencapsulation 
 
3) Encapsulation Efficiency = 100 X Encapsulation / Amount of DOX used 
 
The Loading Capacity of the synthesized dendrimer nanoclusters were calculated using the 
formula 
4) Loading Capacity = Encapsulation (mg) / Weight of the sample obtained after 
lyophilization  
 
2.8 In vitro drug release kinetic studies 
 
Drug release tests were conducted for the samples of G3-CBA-PEG/DOX using G3/DOX as a 
control sample. The samples were filtered using a 0.22 μm filter, and then 10 μg of the sample 
was dissolved in 0.5 mL of water and was contained in a dialysis membrane (Spectrum
®
 labs) 
of MWCO of 3500 Da. The dialysis bag was sealed and suspended into 5 mL of PBS at 
different pH (5, 6.5 and 7.4). All the systems were kept at 37 °C. At specific time points (1, 2, 
4, 6, 8, 24, 48, 120, 216, 312, 456, 552, 840, 1008, 1128 hrs), 100 μL of the buffer medium 
was taken out for analysis and the volume replenished with the corresponding buffer solution 
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then, the aliquots were taken and read at 590 nm using a micro plate reader. A fluorescence 
spectrophotometer (model Victor3TM 1420, PerkinElmer) was used to determine the DOX 
content in the removed aliquots. The redox-sensitivity of the nanosystems was investigated in 
the presence of different concentrations of TGA (0.05, 0.1, 1 and 2 mM) to study their release 
behaviours. 
 
2.9 Biological evaluation 
 
Cal-72 cells (an osteosarcoma cell line) were continuously grown in the cell culture dishes 
with  Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 1% (v/v) of antibiotic and antimycotic 100x solution (AA), 1% (v/v) of L-
Glutamine (Glut) 100x.  All the reagents mentioned here were purchased from Gibco. The 
culture was maintained at 37 °C under humid conditions in incubator with 5 % CO2, and the 
medium was replaced every 3 days. 
To check if the G3-CBA-PEG/DOX nanoclusters are therapeutically active, one day before 
experiments, cells were plated into 48-well plates at a density of 1 × 10
4
 cells per well in the 
DMEM complete medium. The next day, the medium was replaced with fresh DMEM 
complete medium containing free DOX・HCl (5 μM) and G3-CBA-PEG/DOX complex at 
the same DOX concentration in PBS buffer (10 μL) and then the cells were incubated for 48 h 
at 37 °C. After treatment with DOX or dendrimer/DOX complexes, cell morphology was 
observed by optical microscopy (Nikon Eclipse TE 2000E inverted microscope). The 
magnification was set at 100× for all samples.  
Resazurin assay (also known as Alamar Blue assay) was performed to the cells to quantify the 
viability. Resazurin solution was added in an amount equal to 10% of the culture medium 
volume and the cultures were kept in incubator for 2-4 h. Samples can be measured 
spectrophotometrically by monitoring the decrease in absorbance at a wavelength of 600 nm. 
Alternatively, samples can also be measured fluorochrome spectrophotometrically by 
monitoring the increase in fluorescence at a wavelength of 590 nm using an excitation 
wavelength of 560 nm.  Each test included a blank containing complete medium without cells. 
After that, the cells were washed 2 times with PBS (pH 7.4) and 3 times with distilled water 
and were analysed using (Nikon Eclipse TE 2000E inverted microscope). 
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For the cell uptake study, cells were plated for 24 h before the incubation. Freshly prepared 
PBS, solutions of DOX, G3/DOX, and samples of G3-CBA-PEG/DOX with different 
G3:CBA ratios  (1:1, 1:2, 1:3, 1:4) with an equivalent DOX concentration (0.5 µM) were then 
added to the cells and were kept at 37 ºC for 2 and 4 h, respectively.  Subsequently, the cells 
have to be washed with sterilized PBS buffer and, simultaneously, fixed with 3.7% (v/v) 
formaldehyde solution and stained with 4’,6-diamidino-2-phenylindole (DAPI, Sigma) for 30 
min to stain the nucleus of the cells. The cells then were washed with PBS solution for further 
analysis by optical fluorescence microscopy (Nikon Eclipse TE 2000E inverted microscope). 
Note:  For the encapsulation of DOX and drug release studies, water-insoluble DOX was 
used, while for cell biological evaluation, water-soluble DOX.HCl was used as a control to 
check the therapeutic activity of the free drug. 
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CHAPTER 3 – RESULTS AND DISCUSSION 
 
3.1 Synthesis and characterization of G3-CBA-PEG dendrimer nanoclusters 
 
G3 PAMAM dendrimers are smaller in size with fewer impurities when compared with 
higher generation dendrimers. These dendrimers show low cytotoxicity when compared with 
the higher generation dendrimers (85). The terminal groups of CBA react with the NH2 
terminal groups of dendrimers resulting in the formation of dendrimer nanoclusters. The 
disulphide crosslink acts as a bridge between two dendrimer units. The most important 
advantage of using this disulphide crosslinked molecule is the degradability when reacted 
with the glutamic groups present inside the cell providing easy release of the drug 
encapsulated in the nanoclusters (104). The polymerization reaction is shown in Figure 9. 
 
Figure 9 – Schematic representation of development of G3-CBA nanoclusters via in situ 
crosslinking of G3 with N,N’-cystamine-bis-acrylamide (CBA).  
The second major step involved in the synthesis was to PEGylate the formed dendrimer 
nanoclusters. But, before the PEGylation reaction, the terminal groups of mPEG were 
activated using EDC for 3 h and the solution mixture was directly added to the solution 
containing G3-CBA dissolved in Ultra-pure water. The reaction mechanisms involved in the 
 34 
 
activation of the carboxylic groups of mPEG-COOH are shown in Figure 10. The by-products 
(isourea) and excess reagents from the reaction mixture were removed by dialysis (122). 
 
Figure 10 – Schematic representation of the reaction steps involved in the activation of 
carboxylic acid groups of mPEG-COOH by EDC (123).  
 
After the activation of the terminal groups of mPEG, the solution was mixed with the 
G3/CBA dendrimer nanoclusters to synthesize the final compound G3-CBA-PEG dendrimer 
nanocluster. CBA is attached covalently to the dendrimer and moreover mPEG-COOH chains 
may provide the cover for the drug encapsulated and increase the circulation time of the 
nanoclusters inside the body (124). Another advantage of using mPEG-COOH is to improve 
the solubility and colloidal stability of the nanoclusters in the medium (125). The PEGylation 
reaction involved in the synthesis of G3-CBA-PEG nanoclusters is shown in Figure 11. 
 After the reaction was completed, the final compound obtained after dialysis and 
lyophilization was a white solid of G3-CBA-PEG dendrimer nanoclusters. 
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Figure 11 – PEGylation of G3-CBA dendrimer nanoclusters. 
 
3.1.1 Characterisation by 
1
H NMR 
 
The first reaction step was to synthesize G3-CBA dendrimer nanoclusters (Figure 9). The 
nanoclusters were then characterised by 
1
H NMR and FTIR. In the 
1
H NMR spectrum of G3-
CBA in D2O (Figure 12), we can see the peaks of CBA protons, (δ=3.41 ppm NHCH2CH2S-
S, 4H) (126). The high intensity of the peak can be observed due to the overlapping of the 
peaks from protons of G3-PAMAM (δ=3.46 CONHCH2) with the protons of CBA as both the 
protons have the same adjacent NH group. After purification with the dialysis of the final 
compound, we suppose that the entire methanol from the compound was removed as no 
specific peak of methyl protons were observed in the spectrum. We also suppose that the 
characteristic peaks representing the CBA are the linked peaks to the dendrimers and all the 
unreacted CBA molecules were removed. Thus, based on the integration, we calculated that 
0.92 molecules of CBA were linked with each dendrimer using G3-PAMAM dendrimer peaks 
as reference. 
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Figure 12 – 1H NMR spectrum of G3-CBA Dendrimer nanoclusters. 
 
In the second step of the reaction (PEGylation), G3-CBA-PEG dendrimer nanoclusters were 
synthesized (Figure 10). In the 
1
H NMR spectrum of G3-CBA-PEG in D2O (Figure 13), we 
can see the characteristic peak of the mPEG protons (–O–CH2CH2 δ=3.71 ppm) (127). We 
assume that the mPEG molecules were interacted covalently and the free unreacted PEG were 
removed during the dialysis. Considering the 
1
H NMR spectra (Figure 12 and 13) we can 
confirm that the reaction was successful and the final product G3-CBA-PEG dendrimer 
nanoclusters were obtained. 
 
 37 
 
 
Figure 13 – 1H NMR spectrum of G3-CBA-PEG Dendrimer nanoclusters. 
 
G3-CBA-PEG dendrimer nanoclusters were then synthesised using different ratios of 
dendrimer to CBA (1:1, 1:2, 1:3 and 1:4). The 
1
H NMR spectrum of all the samples (G3-
CBA-PEG 1:1, G3-CBA-PEG 1:2, G3-CBA-PEG 1:3, G3-CBA-PEG 1:4) shows that the 
reaction was successful as we can see the characteristic peaks of CBA (NHCH2CH2S-S, group 
δ=3.41 ppm) (126) and the characteristic peaks of mPEG (–O–CH2CH2 δ=3.71 ppm) (127) in 
the spectrum (Figure 14). The 
1
H NMR spectra of the samples show no shift between the 
compounds.  The peaks obtained at δ= 1.353 ppm and δ= 4. 284 ppm may be the peaks from 
any intermediate by-products or from the impurities during the PEGylation reaction which 
can be observed in the spectrum. The ratios of CBA to dendrimer obtained were very less 
than expected when calculated based on 
1
H NMR spectrum. The obtained ratio of CBA to 
dendrimer is shown in Table 3. 
The most important reason for this result is due to the formation of clusters with some active 
reactive sites left inside the cluster, further not reacting with the CBA molecules. The 
conversion rate is normal, since not all CBA will react with the amino groups due to the 
limitation of the reactivity under the current synthetic conditions. 
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Table 3 – Calculated ratios of G3-CBA dendrimer nanoclusters. 
 
CBA ratios calculated for the reaction      Expected Ratios      Calculated   ratios of CBA 
                  
                      1:1                                                   1                                    0.92 
                      1:2                                                   2                                    1.21 
                      1:3                                                   3                                    1.48 
                      1:4                                                   4                                    1.79 
 
The ratios of mPEG to the dendrimer were also found to be very less when compared with the 
ratio used for the synthesis. The possible explanation for this phenomenon may be due to the 
insufficient reactive groups left on the pheriphery of the dendrimer after polymerisation with 
CBA. Another reason resulting in the lower ratio can be caused during the activation of 
terminal carboxylic groups of mPEG where not all the terminal groups were activated. The 
obtained mPEG ratios to dendrimer are mentioned below in Table 4. 
 
Table 4 – Calculated ratios of G3-CBA-PEG dendrimer nanoclusters. 
 
G3-CBA ratios           mPEG ratios calculated for reaction           Obtained G3:mPEG ratio                  
G3: mPEG 
           1:1                                                   1:5                                                             1:2.4 
           1:2                                                   1:5                                                             1:2.4 
           1:3                                                   1:5                                                             1:2.3 
           1:4                                                   1:5                                                             1:2.2 
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Figure 14 – 1H NMR spectrum of G3-CBA-PEG dendrimer nanoclusters at different ratios, 
from the bottom to top (1:1, 1:2, 1:3, and 1:4). Peak A is the characteristic peak of PEG as 
shown in Figure 13 and peak B is the characteristic peak of CBA as shown in Figure 12. 
 
3.1.2 Characterisation by FTIR 
 
To confirm the conjugation of CBA/dendrimers and their following PEGylation reactions, 
FTIR analysis was also performed for the final product G3-CBA-PEG dendrimer nanoclusters 
and also for the intermediate compound (G3-CBA). In the FTIR spectrum (Figure 15) we can 
observe the characteristic peaks of the materials (G3-PAMAM, CBA and mPEG-COOH) 
which are used in the reaction. The detailed peak list is given below; 
Characterstic peaks of mPEG (128): 
O-H Stretching: 3441 cm
−1
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C-H stretching: 2878 cm
−1
 
C-H extended stretching: 1464 and 1343 cm
−1
 
O-H and C-O-H stretching: 1279 and 1074 cm
−1
 
Characteristic peaks of G3-PAMAM dendrimer (129): 
N-H band at 3280 cm
−1
  
C=O band at 1645 cm
−1
 and  
N-H bending at 1556 cm
−1
 
Characteristic peaks of CBA S-S band at 1229 cm
−1 
 
 
Figure 15 – FTIR spectrum of G3-CBA-PEG dendrimer nanoclusters. 
The peak representing CBA show very less intensity in the compound G3-CBA-PEG when 
compared with the free CBA peak due to the formation of clusters. The detailed spectrum and 
peak integration of the starting materials (G3-PAMAM, CBA and mPEG-COOH) and the 
intermediate compounds are shown in ANNEX II (Figure 30, 31 and 32). 
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3.2 Analysis of encapsulation of DOX to G3-CBA-PEG dendrimer nanoclusters 
 
Encapsulation of DOX in the G3-CBA-PEG dendrimer nanoclusters was performed using the 
procedure reported by Xiangyang Shi et Al. (130) (Figure 16). The encapsulation efficiency 
and the loading capacity were studied using UV-Visible spectroscopy considering G3-
PAMAM/DOX as the control sample. The encapsulation efficiency of G3-CBA-PEG 
increased when compared to that of G3/DOX (Figure 17) but when the ratio of CBA to 
dendrimer increased, the encapsulation efficiency of DOX gradually decreased. We suspect 
this phenomenon is due to the formation of nanoclusters of large size. When the sizes of the 
nanoclusters are increased, the surface area decreases which results in the poor adsorption of 
the drug on the surface of the nanoclusters. Another reason can be the close packing of the 
nanoclusters which prevents the entry of drug resulting in poor encapsulation. The 
encapsulation efficiencies of G3-CBA-PEG/DOX at different ratios are shown (Table 5). The 
loading capacity of G3/DOX and G3-CBA-PEG/DOX were calculated based on the results of 
encapsulation efficiency and the total weight of the sample obtained after lyophilization. The 
results show that the loading capacity of G3-CBA-PEG/DOX increased when compared with 
G3/DOX, but gradually decreased when the ratio of CBA to dendrimer is increased (Figure 
18). 
 
Figure – 16 Schematic representation of encapsulation of DOX to G3-CBA-PEG dendrimer 
nanoclusters. 
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Table 5 – Calculated encapsulation efficiencies of DOX for the compounds G3/DOX and G3-
CBA-PEG/DOX at different ratios. 
 
  Name of the sample                                                           Encapsulation efficiency, wt% 
 
G3/DOX                                                                                                       63.56  +  1.2 
G3-CBA-PEG (1:1)                                                                                      66.17  +  0.4 
G3-CBA-PEG (1:2)                                                                                      57.36  + 0.41 
G3-CBA-PEG (1:3)                                                                                      55.47  + 0.25 
G3-CBA-PEG (1:4)                                                                                      53.34  + 0.63 
 
Note that the encapsulation of DOX to dendrimer nanoclusters was repeated for 3 times and 
the average values with standard deviations are reported. 
 
Figure 17 – Comparison of loading capacities of G3/DOX and G3-CBA-PEG/DOX. 
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Figure 18 – Comparison of loading capacities of G3-CBA-PEG/DOX at different ratios. 
 
3.3 Hydrodynamic analysis 
 
The size analysis of G3-CBA-PEG and the drug encapsulated G3-CBA-PEG/DOX were 
measured using the dynamic light scattering (DLS) technique. The samples were filtered 
using a 0.22 μm filter before analysis. The temperature (23 oC) remained constant all along 
the analysis. The sizes of the samples increased with the ratio of CBA due to the formation of 
the clusters of higher radius for both drug free and drug loaded nanoclusters, which are shown 
in Figure 19 and Figure 20.  When the ratio of CBA increased, more number of molecules 
react with the terminal groups of G3-PAMAM which bring other dendrimer units closer by 
crosslinking while forming the clusters. This results in the formation of clusters with bigger 
size. The increase in the size of the drug loaded nanoclusters is due to the formation of 
supramolecular assembly of the drug and dendrimer nanoclusters. The drug molecules 
perhaps have occupied the outer terminal space between the branches of dendrimers and the 
other molecules around the surface of the mPEG molecules which results in the increase of 
size when compared with drug non-loaded samples. 
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Figure 19 –Hydrodynamic sizes of G3-CBA-PEG samples at different ratios of CBA to 
dendrimer. 
 
 
Figure 20 –Hydrodynamic sizes of G3-CBA-PEG/DOX samples at different ratios of CBA to 
dendrimer. 
 
3.3.1 Study of stability of the synthesised NPs 
 
100 μg of the G3-CBA-PEG (Figure 21) and G3-CBA-PEG/DOX (Figure 22) samples of 
different ratios were dissolved in 1 mL water and 1 mL PBS (pH 7.4) separately, and were 
kept at room temperature. The samples were analysed every 24 h for 7 days. The sizes of the 
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samples were measured at regular interval of time using DLS technique. No agglomerations 
of the particles were seen during this period and the sizes of the samples remained constant. 
From these data (ANNEX III), we can say that the samples are stable under similar 
physiological conditions observed in the body and will not agglomerate during the period of 
time and are capable of reaching the tumour cells without degrading. These types of systems 
can be promising vehicles for drug delivery. 
 
Figure 21 – Z-average sizes of G3-CBA-PEG (1:1, 1:2, 1:3, and 1:4) samples during a period 
of 7 days. 
 
Figure 22 – Z-average sizes of G3-CBA-PEG/DOX (1:1, 1:2, 1:3, and 1:4) samples during a 
period of 7 days. 
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3.4 Evaluation of drug release in-vitro at different pH conditions 
 
Drug release tests were performed for G3/DOX and G3-CBA-PEG/DOX samples to study 
their drug release behaviour’s in PBS (pH 7.4, 6.5 and 5.0). The drug release profiles of 
G3/DOX and G3-CBA-PEG/DOX are shown in Figure 23 and Figure 24.  
 
Figure 23 – Cumulative Drug release of DOX from G3/DOX in PBS buffer with different pH 
conditions at 37 
0
C. 
  
 
Figure 24 – Cumulative Drug release of DOX from G3-CBA-PEG/DOX (G3:CBA 1:1) at 
different pH conditions at 37 
0
C. 
For the in vitro drug release studies the samples were sealed tightly using dialysis membrane 
(MWCO 3500) and were suspended into PBS buffers (pH 7.4, 6.5, and 5.0) and were 
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contained in 15 mL poly centrifuge tubes. The tubes containing the samples were kept in 
incubator at 37 
o
C.  
For antitumor therapeutic applications, the encapsulated DOX should be effectively released 
into the cytoplasm and reach the nucleus to exert its biological activity (131). To understand 
the release ability of G3-CBA-PEG/DOX nanocomplexes, their cumulative release profiles 
were investigated in PBS solution at different pH values (7.4, 6.5, and 5.0), as a function of 
soaking time (Figure 24). On the other hand, the release of DOX from the G3-CBA-
PEG/DOX seemed to be enhanced by decreasing the pH value, revealing that the 
nanocomplexes are pH sensitive. In this case, the G3-CBA-PEG/DOX offered a significantly 
accelerated DOX release ability at pH 6.5 (conditions mimicking the extracellular 
environment of a solid tumor)  and pH 5.0 acidic conditions that mimic the endo-lysosomal 
internal milieu compared to that at physiological pH conditions, thus possibly to result in an 
improved drug release ability and anticancer efficacy.  
 
3.4.1 Drug release kinetics at reducible intracellular mimic conditions 
 
To understand the release rates of the synthesized compound in the body, drug release of G3-
CBA-PEG/DOX was studied under reducible intracellular mimic conditions using TGA 
medium and G3/DOX (Figure 25) was kept as a standard to compare the release profiles. 
TGA medium have free thiol groups which provides the similar conditions observed in the 
cells.  In 0.05mM TGA medium the sample G3-CBA-PEG/DOX showed enhanced release 
profile when compared with the release profile at normal PBS 7.4 (Figure 26). This is due to 
the reaction of the cross linkage present between the dendrimers. The disulphide cross link 
reacts instantly with the thiol groups present in the TGA medium, hence leading to the 
cleavage of the nanoclusters to promote the drug release (94). The release profile in TGA 
medium followed a biphasic pattern showing a rapid release in the beginning and a sustained 
release after a period of time.  
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Figure 25 – Comparison of Cumulative drug release of DOX from G3/DOX in PBS buffer 
(pH 7.4) and 0.05 mM TGA medium. 
 
 
Figure 26 – Comparison of Cumulative drug release of DOX from G3-CBA-PEG/DOX 
(G3:CBA 1:1) in PBS buffer (pH 7.4) and 0.05 mM TGA medium. 
The drug release was also conducted at different concentrations of TGA. As shown in Figure 
35, the further increase of TGA concentration seems to result in a decrease of the whole 
absorbance intensity, possibly because higher TGA concentration produced a too much 
reducible environment to induce a modification of the DOX chemical structure.  The 
complete drug release profile of G3/DOX and G3-CBA-PEG/DOX are presented in ANNEX 
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IV (Figure 34-42). The aliquots for the drug release studies were studied using fluorescence 
spectroscopy.  
 
3.5 Evaluation of cytotoxicity 
 
The cytotoxicity of the DOX-loaded nanocomplexes was quantitatively evaluated using CAL- 
72 cells (an osteosarcoma cell line) through the resazurin reduction assay (Figure 27). It can 
be seen that the cells treated with G3-CBA-PEG showed a higher viability than the 
corresponding G3 dendrimers, suggesting the introduction of the PEG onto the nanoclusters is 
helpful to improve the biocompatibility of G3. The G3-CBA-PEG/DOX nanoclusters 
exhibited an obviously higher anticancer cytotoxicity to CAL-72 cells than the corresponding 
drug free systems, suggesting that the cytotoxic effect was only due to the drug loaded within 
the nanocomplexes. The increase of CBA/G3 ratio seems to reduce the anticancer cytotoxicity 
of the DOX-loaded nanoclusters, probably because the high concentration of CBA which acts 
as crosslinker leads to the formation of a more compact structure, which limited the DOX 
release ability from the nanoclusters. Even though the cytotoxicity of G3/DOX was higher 
towards these cells as compared to G3-CBA-PEG/DOX, but, for in vivo applications, one 
should expect the latter could exhibit a longer circulation period than the former due to the 
presence of PEG, thus possibly resulting in a higher effect on the tumor site due to the 
prolonged EPR effect (92, 94, 120, 122).  
 
Figure 27 – Comparison of cell viability of CAL- 72 cells treated with 0.5 μM (blue) and 1.5 
μM (red). The data are expressed as mean ± S.D. 
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3.6 Cellular uptake G3-CBA-PEG/DOX  
 
The drug delivery systems should be effectively taken up by cells and be able to deliver the 
drug inside them. As DOX is a fluorescent molecule, its internalization by CAL-72 cells can 
be followed by fluorescence microscopy. Figure 28 shows the bright field and fluorescence 
microscope images of CAL-72 cells after 48 h in culture with DMEM (control), free DOX 
(1.5 μM), G3/DOX and G3-CBA-PEG/DOX with an equivalent amount of DOX (1.5 μM) 
diluted in the cell culture medium. The results show that a higher reddish intensity can be 
observed inside both cytosol and nucleus (especially in nucleus) after the cells were treated 
with the G3-CBA-PEG/DOX (G3/CBA is 1/4) for 48 h, compared to free DOX and the 
corresponding G3/DOX experiments. This higher DOX accumulation and enhanced 
anticancer activity may be attributed to the higher cell uptake of the G3-CBA-PEG/DOX 
nanoclusters and the improved DOX release intracellularly (probably due to reducible 
intracellular environments) (92), as well as to an acid-facilitated DOX release from the endo-
lysosomal compartments to the nucleus. The above results indicate that the G3-CBA-
PEG/DOX nanoclusters are able to effectively deliver DOX inside cancer cells. 
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Figure 28 – Fluorescence microscopy images of CAL-72 cells, treated with G3-PAMAM  for 
48 hours (A), G3/DOX (B),  PBS (pH 7.4) (C), DOX.HCl (D), G3-CBA-PEG (1:1) (E), G3-
CBA-PEG (1:2) (F), G3-CBA-PEG (1:3) (G), G3-CBA-PEG (1:4) (H), G3-CBA-PEG/DOX 
(1:1) (I), G3-CBA-PEG/DOX (1:2) (J), G3-CBA-PEG/DOX (1:3) (K), G3-CBA-PEG/DOX 
(1:4) (L). In all cases, the DOX concentration was kept at 1.5 μM. For each panel, the images 
from left to right show bright field (series 1), blue fluorescence channel detecting the DAPI 
dye (series 2), red fluorescence channel detecting DOX (series 3), and merged images of blue 
fluorescence and red fluorescence channel (series 4). All the images were collected under 
similar instrumental conditions. 
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Summary 
 
In this work, redox-sensitive G3-CBA-PEG dendrimer nanoclusters were synthesised by in 
situ crosslinking of low generation G3 dendrimers using CBA, followed by conjugation with 
mPEG-COOH. These nanoclusters were successfully encapsulated with DOX. The formed 
G3-CBA-PEG/DOX nanocomplexes were stable and displayed acid-accelerated drug release 
behaviour in tumor-mimic microenvironments and enhanced drug release property under 
intracellular reducible conditions. These merits, together with their enhanced 
biocompatibility, indicate that the G3-CBA-PEG/DOX nanocomplexes are able to effectively 
deliver DOX inside cancer cells. This work gives a new insight for the rational design of an 
optimal degradable platform for the intracellular delivery of therapeutic agents. 
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ANNEX I – 1H NMR spectra with integration and identifications of peaks. 
 
 
Figure 29 – 1H NMR spectrum of G3-PAMAM dendrimer in D2O with integration and peak 
identifications. 
A = CONHCH2; B = CONHCH2CH2NH2; C = NCH2CH2CONH; D = CH2CH2NR2; E = 
CH2CONH. (76). 
 
G3-PAMAM dendrimer with terminal groups, the black ball represents the core structure of 
the dendrimer. 
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ANNEX II – FTIR spectra with identifications of peaks. 
 
Preparation of Pellets for FTIR analysis 
G3-PAMAM dendrimer was 5 mg was mixed with 20 mg of KBr and was finely grinded until 
the mixture has the consistency of fine flour. The mixture was then transferred into the 
cylindrical bore and evenly distributed. The mixture was subjected to a hydraulic pressure of 
10 tons, after 1 minute the pressure was released. The sample was found to be evenly 
distributed and the disk was translucent. Then the sample disk was analysed using FTIR 
spectroscopy.  
 
 
 
Figure 30 – FTIR spectrum of G3.NH2 PAMAM dendrimer with identification of peaks. 
 
Characteristic peaks of G3-PAMAM dendrimer  
N-H band at 3280 cm
−1
 
C=O band at 1645 cm
−1
 and  
N-H bending at 1556 cm
−1
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Figure 31 – FTIR spectrum of mPEG with identification of peaks. 
 
Characteristic peaks of mPEG observed in FTIR spectrum  
O-H Stretching: 3441 cm
−1
 
C-H stretching: 2878 cm
−1
 
C-H extended Stretching: 1464 and 1343 cm
−1
 
O-H AND C-O-H stretching: 1279 and 1074 cm
−1
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Figure 32 – FTIR spectrum of CBA with identification of peaks. 
 
The characteristic peaks observed in the FTIR spectrum of CBA 
 S-S band at 1229 cm
−1
,  
N-H band at 3253 cm
−1
,  
C=O band at 1645 cm
−1
and  
=CH2 at 3066 cm
−1.
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ANNEX III – Study of stability of particles. 
 
Samples without DOX G3-
CBA-PEG 
     
G3:CBA day 1 day 2 day 3 day 4 day 5 day 6 day 7 
01:01 172.8 ± 
1.21 
172.91 ± 
1.45 
172.5 ± 
0.9 
172.68 ± 
1.24 
172.65 ± 
1.37 
172.84 ± 
1.89 
172.75 ± 
1.54 
01:02 175.1 ± 
0.54 
175.21 ± 
1.67 
175.69 ± 
1.24 
175.43 ± 
1.05 
175.58 ± 
1.21 
175.37 ± 
1.4 
175.25 ± 
1.2 
01:03 285.4 ± 
3.5 
285.3 ± 
6.4 
285.57 ± 
5.2 
285.9 ± 
4.8 
285.85 ± 
3.28 
285.38 ± 
4.1 
285.44 ± 
5.06 
01:04 411 ± 
8.05 
411.4 ± 
3.51 
411.21 ± 
4.08 
411.49 ± 
6.2 
411.32 ± 
5.9 
411.15 ± 
7.9 
411.12 ± 
6.8 
Samples with DOX G3-CBA-
PEG/DOX 
     
G3:CBA day 1 day 2 day 3 day 4 day 5 day 6 day 7 
01:01 190.1 ± 
2.87 
190.85 ± 
3.23 
190.72 ± 
5.71 
190.6 ± 
4.83 
190.43 ± 
6.21 
190.21 ± 
4.12 
189.8 ± 
7.65 
01:02 323.8 ± 
1.59 
323.5 ± 
2.66 
323.1 ± 
2.4 
322.7 ± 
3.09 
322.5 ± 
4.8 
322.3 ± 
3.78 
322.1 ± 
4.28 
01:03 369.9 ± 
5.44 
369.7 ± 
4.32 
368.8 ± 
6.84 
368.2 ± 
3.87 
368.02 ± 
5.61 
367.92 ± 
4.87 
367.77 ± 
6.38 
01:04 446.7 ± 
7.52 
446.3 ± 
8.65 
446.1 ± 
7.94 
445.8 ± 
8.21 
445.5 ± 
8.79 
445.2 ± 
9.53 
444.21 ± 
10.87 
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ANNEX IV – Study of drug release kinetics. 
 
Figure 33 – Calibration curve of DOX by fluorescence spectroscopy. 
 
For measuring the standard curve of DOX by fluorescence spectroscopy, DOX was prepared 
in concentrations of 0.25, 0.5, 1, 2, and 4µg/mL. The samples were taken in a micro plate 
reader (100 µL each sample) and the fluorescence was measured at 590 nm. 
 
 
Figure 34 – Cumulative drug release of G3/DOX at different concentrations of TGA 
compared with release profile at PBS (pH 7.4). 
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Figure 35 – Cumulative drug release of G3-CBA-PEG/DOX (G3:CBA 1:1) at different 
concentrations of TGA compared with release profile at PBS (pH 7.4). 
 
 
Figure 36 – Comparison of cumulative drug release of G3/DOX and G3-CBA-PEG/DOX 
(G3:CBA 1:1) at PBS (pH 7.4). 
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Figure 37 – Comparison of cumulative drug release of G3/DOX and G3-CBA-PEG/DOX 
(G3:CBA 1:1) at PBS (pH 6.5). 
 
 
Figure 38 – Comparison of cumulative drug release of G3/DOX and G3-CBA-PEG/DOX 
(G3:CBA 1:1) at PBS (pH 5.0). 
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Figure 39 – Comparison of cumulative drug release of G3/DOX and G3-CBA-PEG/DOX 
(G3:CBA 1:1)  at TGA 0.05 mM. 
 
Figure 40 – Comparison of cumulative drug release of G3/DOX and G3-CBA-PEG/DOX 
(G3:CBA 1:1) at TGA 0.1 mM. 
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Figure 41 – Comparison of cumulative drug release of G3/DOX and G3-CBA-PEG/DOX 
(G3:CBA 1:1) at TGA 1 mM. 
 
 
Figure 42 – Comparison of cumulative drug release of G3/DOX and G3-CBA-PEG/DOX 
(G3:CBA 1:1) at TGA 2 mM. 
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ANNEX V – Cytotoxic studies of CAL-72 cell line with different concentrations of DOX. 
 
Figure 43 – Comparison of cell viability of DOX.HCl (Blue column), G3/DOX (Red column), 
G3-CBA-PEG/DOX (G3:CBA 1:1), (Green column) and G3-CBA-PEG (G3:CBA 1:1) 
(Violet column) at different concentrations. 
Note that cells treated with PBS 7.4 and DMEM medium are not shown in the Figure and are 
reported in the Figure 22 and 23. The concentration of the DOX is kept constant for all the 
samples at specified concentration except the sample without DOX. 
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